{
  "title": "Paper_201",
  "abstract": "pmc Virchows Arch Virchows Arch 365 springeropen Virchows Archiv 0945-6317 1432-2307 pmc-is-collection-domain yes pmc-collection-title Springer PMC12488741 PMC12488741.1 12488741 12488741 40232379 10.1007/s00428-025-04102-9 4102 1 Original Article A practical approach to better identify NTRK 1–3 http://orcid.org/0000-0001-5704-7721 Haberecker Martina 1 Kuerten Pauline 1 http://orcid.org/0000-0002-3848-144X Vetter Viola Katharina 1 Malega Francesca 1 http://orcid.org/0000-0002-7986-2839 Moch Holger 1 2 http://orcid.org/0000-0001-9621-8511 Pauli Chantal chantal.pauli@usz.ch 1 2 1 https://ror.org/01462r250 grid.412004.3 0000 0004 0478 9977 Department of Pathology and Molecular Pathology, University Hospital Zurich, 2 https://ror.org/02crff812 grid.7400.3 0000 0004 1937 0650 Medical Faculty, University Zurich, 15 4 2025 2025 487 3 498144 671 680 12 1 2025 19 3 2025 4 4 2025 15 04 2025 03 10 2025 03 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by/4.0/ Open Access http://creativecommons.org/licenses/by/4.0/ Pan-Trk immunohistochemistry has become an affordable screening tool for tumors harboring NTRK1 - 3 EPR17341 EPR17341 NTRK EPR17341 NTRK1 EPR17341 NTRK1 - 3 Supplementary Information The online version contains supplementary material available at 10.1007/s00428-025-04102-9. Keywords NTRK Immunohistochemistry Mesenchymal tumors Antibody clone http://dx.doi.org/10.13039/100007013 F. Hoffmann-La Roche University of Zurich Open access funding provided by University of Zurich pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer-Verlag GmbH Germany, part of Springer Nature 2025 Introduction The discovery and characterization of oncogenic NTRK 1 2 NTRK1 - 3- 3 NTRK1 - 3 4 6 NTRK1 - 3- 4 BCOR 5 7 8 9 10 NTRK1 - 3 Material and methods Sample selection Eight hundred nine patients diagnosed with a mesenchymal neoplasm in the Department of Pathology and Molecular Pathology, University Hospital Zurich (USZ), Switzerland, between 1997–2023, were included in this study. Archival FFPE from excisions and resection specimens were selected and the diagnosis was confirmed by two expert pathologists (C.P., M.H.). Tumor types included in this study were: adipocytic sarcomas ( n n n n n n n n n n n n n n n n n n n n NTRK1 TPR::NTRK1 LMNA::NTRK1 1 1 Table 1 Mesenchymal tumors with positive pan-Trk Immunohistochemistry Entity EPR17341 N A7H6R N Adipocytic sarcomas 23/82 (14%) 0/25 – UPS 19/78 (24%) 3/31 (10%) Leiomyosarcoma, NOS 6/63 (1%) 0/16 – Synovial sarcoma 17/64 (26%) 0/64 – MPNST 8/35 (23%) 1/17 (6%) SFT 7/33 (21%) 3/33 (9%) Ewing sarcoma 12/31 (39%) 2/22 (9%) Gastrointestinal stromal tumor 16/36 (44%) 7/26 (27%) Angiosarcoma 0/26 – 0/12 – Myxofibrosarcoma 0/22 – 0 – Rare sarcomas of uncertain differentiation 9/22 (41%) 1/22 (5%) Epitheloid sarcoma 2/9 (22%) 0/9 – Extraskeletal myxoid chondrosarcoma 3/6 (50%) 1/6 (17%) Intimal sarcoma 4/7 (57%) 0/7 – Rare fusion positive sarcomas 9/22 (41%) 1/17 (9%) Alveolar soft part sarcoma 0/2 – 0 – DSRCT 2/2 (100%) 0/2 – CIC-rearranged sarcoma 0/3 – 0 – Sarcoma with BCOR genetic alterations 4/7 (57%) 0/7 – Clear cell sarcoma of soft tissue 3/8 (37%) 1/8 (13%) Fibroblastic and myofibroblastic tumor 1/18 (6%) 0/18 – Skin sarcomas 6/19 (32%) 2/19 (11%) Dermatofibrosarcoma protuberans 6/14 (43%) 2/14 (14%) Kaposi and pleomorphic dermal sarcoma 0/5 – 0/5 – Osteosarcoma 5/174 – 2/5 (40%) Chondrogenic sarcomas 3/16 (19%) 0/3 – Endometrial stroma sarcoma 4/12 (33%) 0/4 – Low-grade sarcoma NOS** 1/5 (20%) 0/1 – Schwannoma 31/37 (85%) 12/31 (39%) Other benign tumor* 1/12 (8%) 0/12 – NTRK fusion positive tumor 3/3 (100%) 3/3 (100%) Total 180/809 (22%) 37/381 (7%) UPS MPNST SFT IMT * ** The presented study was conducted following regional/cantonal and institutional guidelines, in compliance with the Helsinki Declaration and after approval by our cantonal ethical review board Zurich (BASEC- 2021–00417). Immunohistochemistry Pan-Trk immunohistochemical stains were performed on full sections using VENTANA pan-Trk ( EPR17341 10 1 EPR17341 n Fig. 1 Scoring: semi-quantitative assessment of staining intensity and pan-Trk immunohistochemistry ( EPR17341 A, D B, E C, F G Molecular testing Molecular testing was performed on FFPE material using commercially available molecular tumor profiling assays, used and validated for routine diagnostics: custom-made Archer Sarcoma Fusion Plex Assays (RNA) detecting 132 fusions, FoundationOne®CDx (DNA), FoundationOne®Heme (DNA and RNA), Sanger sequencing for entity specific fusion detection ( SSX::SYT FUS::DDIT3 EWSR1::FLI1 KIT PDGFRA 2 6 n EPR17341 n EPR17341 Fluorescence in situ hybridization (FISH) was performed using the ZytoLight SPEC NTRK1 PRCC::NTRK1- Statistical analyses Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 29.0. (Armonk, NY: IBM Corp. Released 2022). For positive predictive values (PPV) and negative predictive values (NPV), prevalence was calculated to be 1.1%, as in addition to the here identified NTRK NTRK 6 11 12 https://github.com/nowthis/sankeymatic Results Mesenchymal tumors with positive pan-Trk (clone EPR17341 Eight hundred nine (809)﻿ mesenchymal neoplasms were immunohistochemically analyzed using the pan-Trk clone EPR17341 1 2 NTRK1 TPR::NTRK1 , LMNA::NTRK1 NF1 1 1 EPR17341 Fig. 2 Pan-Trk immunohistochemistry. A EPR17341 NKTR NTRK B EPR17341 n NTRK High rate of false pan-Trk (clone EPR17341 27.6% (223/809) of all included tumors, harbored a confirmed pathogenic gene fusion. 45.2% (80/177) of all false positive pan-Trk ( EPR17341 BCOR EPR17341 ZBTB16::ABL1 Interestingly, no false positivity was found in CIC Pan-Trk antibody clone-dependent staining sensitivity for mesenchymal tumors All 180 positive cases for pan-Trk ( EPR17341 NTRK1 n NTRK wild type n n n n n n n n n n Of these 34 false positive cases, 11 tumors showed a strong expression (32%, score 3), 14 tumors a moderate expression (41%, score 2) and 9 tumors a weak expression (27%, score 1). The false positive staining intensity with clone A7H6R was stronger in 43% (15/34), the same in 46% (16/34) and weaker in 11% (4/34) of the cases compared to clone EPR1734. A comparison of distribution of staining intensities can be found in Fig. 2 BCOR n n n 1 2 Interrater reliability across different clones ICC for pan-Trk expression ( EPR17341 ĸ EPR17341 n ĸ ĸ n ĸ False positive staining per compartment (cytoplasm, membranous, and nuclear) False positive staining with clone ERP1734 was mainly seen in the cytoplasm 97% (173/177). The majority of these cases (60%) showed weak expression (score 1) followed by 29% with moderate expression (score 2) and 11% with strong expression (score 3). One clear cell sarcoma presented with a weak membranous expression and nuclear expression was seen in one MPNST (weak, score 1) as well as one intimal sarcoma with a strong expression harboring a ZBTB16::ABL1 2 NTRK fusion-positive spindle cell neoplasms A 3-year-old male patient presented with a 17-cm mass in the pancreas head. Total excision showed infiltration into the stomach, bowel and liver. The tumor was formed by a cellular population of spindled cells in a loose fashion (Fig. 3 NTRK1::TPR CDKN2 A/B Fig. 3 NTRK A, D NTRK1::TPR B, E NTRK1::TPR C, F NTRK1::LMNA D E F The second case was a 54-year-old male patient with a 9-cm mass at the lower left extremity. The tumor composed of loose spindle cells including some multinucleated, pleomorphic cells (Fig. 3 EPR17341 NTRK1::TPR CDKN2B The last case was an 8-year-old male patient with a soft tissue mass in the left foot, formed by a cellular population of spindled cells in short fascicles in a storiform way, which later metastasized to regional lymph nodes (Fig. 3 NTRK::LMNA PRCC:NTRK1-rearrangements During our routine molecular diagnostic work up (period 2022–2024), we found a non-pathogenic PRCC::NTRK1- S18::SSX MYH9::USP6 4 NTRK1 NKTR1 4 Fig. 4 A PRCC::NTRK1 B B C D Discussion The screening for a NTRK1 - 3 5 7 NTRK1 - 3 10 7 Forty-five percent of the false positive stained cases harbored a non- NTKR1 - 3 BCOR EWSR1::WT1 NTRK3 8 13 14 NTRK3 EPR17341 15 EPR17341 EPR17341 6 EPR17341 EPR17341 Weak to strong positivity for pan-Trk immunohistochemistry was seen in 85% (31/37) of schwannomas using EPR17341 16 NTRK NF1 NTRK- NF1 17 18 It is of utmost relevance to identify patients that are benefitting from targeted therapy using TRK receptor tyrosine kinase inhibitors. Therefore, it is necessary to identify the tumors that harbor a pathogenic kinase fusion. As more institutions have access to molecular testing and also broader testing is performed, it also becomes very important, that only true pathogenic fusions are reported to not mislead any clinical management. We have recurrently detected a PRCC::NTRK1- NKTR1 19 NTRK1 NTRK 20 The proposed NTRK NTRK 9 21 22 NTRK 23 27 NTRK1 - 3 Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (XLSX 15 KB) Supplementary file2 (XLSX 12 KB) Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements We are grateful for technical support to complement sections and stains to Susanne Dettwiler, Fabiola Prutek, and André Fitsche, Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland. Author contribution M.H. and C.P. performed study concept and design; M.H., P.K., F.M., and V.V. performed data generation; M.H. performed data analysis. M.H. and C.P. interpreted data and performed writing, review, and revision of the paper. All authors read and approved the final paper. Funding Open access funding provided by University of Zurich. This work was supported by F. Hoffmann-La Roche (financial support for FoundationOne®Heme testing and provision of reagents for the immunohistochemistry). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author upon request. Declarations Ethics approval and consent to participate The present study was conducted following regional/cantonal and institutional guidelines, in compliance with the Helsinki Declaration and after approval by our cantonal ethical review board Zurich (BASEC- 2021–00417). Conflict of interest The authors declare no competing interests. References 1. Drilon A Laetsch TW Kummar S DuBois SG Lassen UN Demetri GD Nathenson M Doebele RC Farago AF Pappo AS Turpin B Dowlati A Brose MS Mascarenhas L Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children N Engl J Med 2018 378 8 731 739 10.1056/NEJMoa1714448 29466156 PMC5857389 Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731–739. 10.1056/NEJMoa1714448 29466156 10.1056/NEJMoa1714448 PMC5857389 2. Drilon A Siena S Ou SI Patel M Ahn MJ Lee J Bauer TM Farago AF Wheler JJ Liu SV Doebele R Giannetta L Cerea G Marrapese G Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer Discov 2017 7 4 400 409 10.1158/2159-8290.Cd-16-1237 28183697 PMC5380583 Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G et al (2017) Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov 7(4):400–409. 10.1158/2159-8290.Cd-16-1237 28183697 10.1158/2159-8290.CD-16-1237 PMC5380583 3. Marchiò C Scaltriti M Ladanyi M Iafrate AJ Bibeau F Dietel M Hechtman JF Troiani T López-Rios F Douillard JY Andrè F Reis-Filho JS ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research Ann Oncol 2019 30 9 1417 1427 10.1093/annonc/mdz204 31268127 Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30(9):1417–1427. 10.1093/annonc/mdz204 31268127 10.1093/annonc/mdz204 4. Hondelink LM Schrader AMR Asri Aghmuni G Solleveld-Westerink N Cleton-Jansen AM van Egmond D Boot A Ouahoud S Khalifa MN Wai Lam S Morreau H Bovee J van Wezel T Cohen D The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis Eur J Cancer 2022 173 229 237 10.1016/j.ejca.2022.06.030 35933886 Hondelink LM, Schrader AMR, Asri Aghmuni G, Solleveld-Westerink N, Cleton-Jansen AM, van Egmond D, Boot A, Ouahoud S, Khalifa MN, Wai Lam S, Morreau H, Bovee J, van Wezel T, Cohen D (2022) The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Eur J Cancer 173:229–237. 10.1016/j.ejca.2022.06.030 35933886 10.1016/j.ejca.2022.06.030 5. Solomon JP Linkov I Rosado A Mullaney K Rosen EY Frosina D Jungbluth AA Zehir A Benayed R Drilon A Hyman DM Ladanyi M Sireci AN Hechtman JF NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls Mod Pathol 2020 33 1 38 46 10.1038/s41379-019-0324-7 31375766 PMC7437403 Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33(1):38–46. 10.1038/s41379-019-0324-7 31375766 10.1038/s41379-019-0324-7 PMC7437403 6. Haberecker M Töpfer A Melega F Moch H Pauli C A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types Histopathology 2023 82 7 1003 1012 10.1111/his.14884 36759438 Haberecker M, Töpfer A, Melega F, Moch H, Pauli C (2023) A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types. Histopathology 82(7):1003–1012. 10.1111/his.14884 36759438 10.1111/his.14884 7. Brčić I Godschachner TM Bergovec M Igrec J Till H Lackner H Scheipl S Kashofer K Brodowicz T Leithner A Szkandera J Liegl-Atzwanger B Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions Mod Pathol 2021 34 2 396 407 10.1038/s41379-020-00657-x 32860002 PMC7817523 Brčić I, Godschachner TM, Bergovec M, Igrec J, Till H, Lackner H, Scheipl S, Kashofer K, Brodowicz T, Leithner A, Szkandera J, Liegl-Atzwanger B (2021) Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Mod Pathol 34(2):396–407. 10.1038/s41379-020-00657-x 32860002 10.1038/s41379-020-00657-x PMC7817523 8. Kao YC Sung YS Argani P Swanson D Alaggio R Tap W Wexler L Dickson BC Antonescu CR NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations Mod Pathol 2020 33 7 1341 1349 10.1038/s41379-020-0495-2 32034283 PMC7329614 Kao YC, Sung YS, Argani P, Swanson D, Alaggio R, Tap W, Wexler L, Dickson BC, Antonescu CR (2020) NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. Mod Pathol 33(7):1341–1349. 10.1038/s41379-020-0495-2 32034283 10.1038/s41379-020-0495-2 PMC7329614 9. Demetri GD Antonescu CR Bjerkehagen B Bovée J Boye K Chacón M Dei Tos AP Desai J Fletcher JA Gelderblom H George S Gronchi A Haas RL Hindi N Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network Ann Oncol 2020 31 11 1506 1517 10.1016/j.annonc.2020.08.2232 32891793 PMC7985805 Demetri GD, Antonescu CR, Bjerkehagen B, Bovée J, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N et al (2020) Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 31(11):1506–1517. 10.1016/j.annonc.2020.08.2232 32891793 10.1016/j.annonc.2020.08.2232 PMC7985805 10 Solomon JP Benayed R Hechtman JF Ladanyi M Identifying patients with NTRK fusion cancer Ann Oncol 2019 30 Suppl_8 viii16 viii22 10.1093/annonc/mdz384 31738428 PMC6859817 Solomon JP, Benayed R, Hechtman JF, Ladanyi M (2019) Identifying patients with NTRK fusion cancer. Ann Oncol 30(Suppl_8):viii16–viii22. 10.1093/annonc/mdz384 31738428 10.1093/annonc/mdz384 PMC6859817 11. Koo TK Li MY A guideline of selecting and reporting intraclass correlation coefficients for reliability research J Chiropr Med 2016 15 2 155 163 10.1016/j.jcm.2016.02.012 27330520 PMC4913118 Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155–163. 10.1016/j.jcm.2016.02.012 27330520 10.1016/j.jcm.2016.02.012 PMC4913118 12. Landis JR Koch GG The measurement of observer agreement for categorical data Biometrics 1977 33 1 159 174 10.2307/2529310 843571 Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174. 10.2307/2529310 843571 13. Ogura K Somwar R Hmeljak J Magnan H Benayed R Momeni Boroujeni A Bowman AS Mattar MS Khodos I de Stanchina E Jungbluth A Asher M Odintsov I Hartono AB Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor Clin Cancer Res 2021 27 4 1184 1194 10.1158/1078-0432.Ccr-20-2585 33229458 PMC8212565 Ogura K, Somwar R, Hmeljak J, Magnan H, Benayed R, Momeni Boroujeni A, Bowman AS, Mattar MS, Khodos I, de Stanchina E, Jungbluth A, Asher M, Odintsov I, Hartono AB et al (2021) Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor. Clin Cancer Res 27(4):1184–1194. 10.1158/1078-0432.Ccr-20-2585 33229458 10.1158/1078-0432.CCR-20-2585 PMC8212565 14. Kim MS Lee WS Lee H Jin W TrkC, a novel prognostic marker, induces and maintains cell survival and metastatic dissemination of Ewing sarcoma by inhibiting EWSR1-FLI1 degradation Cell Death Dis 2022 13 9 836 10.1038/s41419-022-05275-w 36171207 PMC9519565 Kim MS, Lee WS, Lee H, Jin W (2022) TrkC, a novel prognostic marker, induces and maintains cell survival and metastatic dissemination of Ewing sarcoma by inhibiting EWSR1-FLI1 degradation. Cell Death Dis 13(9):836. 10.1038/s41419-022-05275-w 36171207 10.1038/s41419-022-05275-w PMC9519565 15. Adam J Stang NL Uguen A Badoual C Chenard MP Lantuéjoul S Maran-Gonzalez A Robin YM Rochaix P Sabourin JC Soubeyran I Sturm N Svrcek M Vincent-Salomon A Multicenter harmonization study of Pan-Trk immunohistochemistry for the detection of NTRK3 fusions Mod Pathol 2023 36 8 100192 10.1016/j.modpat.2023.100192 37084942 Adam J, Stang NL, Uguen A, Badoual C, Chenard MP, Lantuéjoul S, Maran-Gonzalez A, Robin YM, Rochaix P, Sabourin JC, Soubeyran I, Sturm N, Svrcek M, Vincent-Salomon A et al (2023) Multicenter harmonization study of Pan-Trk immunohistochemistry for the detection of NTRK3 fusions. Mod Pathol 36(8):100192. 10.1016/j.modpat.2023.100192 37084942 10.1016/j.modpat.2023.100192 16. Bhatheja K Field J Schwann cells: origins and role in axonal maintenance and regeneration Int J Biochem Cell Biol 2006 38 12 1995 1999 10.1016/j.biocel.2006.05.007 16807057 Bhatheja K, Field J (2006) Schwann cells: origins and role in axonal maintenance and regeneration. Int J Biochem Cell Biol 38(12):1995–1999. 10.1016/j.biocel.2006.05.007 16807057 10.1016/j.biocel.2006.05.007 17. Kobayashi H Makise N Shinozaki-Ushiku A Zhang L Ishibashi Y Ikegami M Tsuda Y Kohsaka S Ushiku T Oda K Miyagawa K Aburatani H Mano H Tanaka S Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene Genes Chromosomes Cancer 2023 62 1 47 51 10.1002/gcc.23089 35906852 Kobayashi H, Makise N, Shinozaki-Ushiku A, Zhang L, Ishibashi Y, Ikegami M, Tsuda Y, Kohsaka S, Ushiku T, Oda K, Miyagawa K, Aburatani H, Mano H, Tanaka S (2023) Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene. Genes Chromosomes Cancer 62(1):47–51. 10.1002/gcc.23089 35906852 10.1002/gcc.23089 18. Hiemcke-Jiwa LS Meister MT Martin E Dierselhuis MP Haveman LM Meijers RWJ Tops BBJ Wesseling P van Diest PJ van Gorp JM Hehir-Kwa JY van Belzen I Bonenkamp JJ van Noesel MM NTRK rearrangements in a subset of NF1-related malignant peripheral nerve sheath tumors as novel actionable target Acta Neuropathol 2023 145 1 149 152 10.1007/s00401-022-02515-3 36331594 PMC9807516 Hiemcke-Jiwa LS, Meister MT, Martin E, Dierselhuis MP, Haveman LM, Meijers RWJ, Tops BBJ, Wesseling P, van Diest PJ, van Gorp JM, Hehir-Kwa JY, van Belzen I, Bonenkamp JJ, van Noesel MM et al (2023) NTRK rearrangements in a subset of NF1-related malignant peripheral nerve sheath tumors as novel actionable target. Acta Neuropathol 145(1):149–152. 10.1007/s00401-022-02515-3 36331594 10.1007/s00401-022-02515-3 PMC9807516 19. Al Assaad M Michaud O Semaan A Sigouros M Tranquille M Phan A Levine MF Gundem G Medina-Martínez JS Papaemmanuil E Manohar J Wilkes D Sboner A Hoda SAF Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets Mod Pathol 2024 37 4 100452 10.1016/j.modpat.2024.100452 38369186 Al Assaad M, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, Levine MF, Gundem G, Medina-Martínez JS, Papaemmanuil E, Manohar J, Wilkes D, Sboner A, Hoda SAF et al (2024) Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets. Mod Pathol 37(4):100452. 10.1016/j.modpat.2024.100452 38369186 10.1016/j.modpat.2024.100452 20. Ameline B Saba KH Kovac M Magnusson L Witt O Bielack S Nathrath M Nord KH Baumhoer D NTRK fusions in osteosarcoma are rare and non-functional events J Pathol Clin Res 2020 6 2 107 112 10.1002/cjp2.158 32022484 PMC7164374 Ameline B, Saba KH, Kovac M, Magnusson L, Witt O, Bielack S, Nathrath M, Nord KH, Baumhoer D (2020) NTRK fusions in osteosarcoma are rare and non-functional events. J Pathol Clin Res 6(2):107–112. 10.1002/cjp2.158 32022484 10.1002/cjp2.158 PMC7164374 21. Wong DD Vargas AC Bonar F Maclean F Kattampallil J Stewart C Sulaiman B Santos L Gill AJ NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm Pathology 2020 52 4 401 409 10.1016/j.pathol.2020.02.004 32278476 Wong DD, Vargas AC, Bonar F, Maclean F, Kattampallil J, Stewart C, Sulaiman B, Santos L, Gill AJ (2020) NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm. Pathology 52(4):401–409. 10.1016/j.pathol.2020.02.004 32278476 10.1016/j.pathol.2020.02.004 22. Weiss LM Funari VA NTRK fusions and Trk proteins: what are they and how to test for them Hum Pathol 2021 112 59 69 10.1016/j.humpath.2021.03.007 33794242 Weiss LM, Funari VA (2021) NTRK fusions and Trk proteins: what are they and how to test for them. Hum Pathol 112:59–69. 10.1016/j.humpath.2021.03.007 33794242 10.1016/j.humpath.2021.03.007 23. Agaram NP, Zhang L, Sung Y-S, Chen C-L, Chung CT, Antonescu CR, & Fletcher CDM (2016) Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. The American Journal of Surgical Pathology 40 https://journals.lww.com/ajsp/fulltext/2016/10000/recurrent_ntrk1_gene_fusions_define_a_novel_subset.14.aspx 10.1097/PAS.0000000000000675 PMC5023452 27259011 24. Haller F Knopf J Ackermann A Bieg M Kleinheinz K Schlesner M Moskalev EA Will R Satir AA Abdelmagid IE Giedl J Carbon R Rompel O Hartmann A Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern J Pathol 2016 238 5 700 710 10.1002/path.4701 26863915 Haller F, Knopf J, Ackermann A, Bieg M, Kleinheinz K, Schlesner M, Moskalev EA, Will R, Satir AA, Abdelmagid IE, Giedl J, Carbon R, Rompel O, Hartmann A et al (2016) Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 238(5):700–710. 10.1002/path.4701 26863915 10.1002/path.4701 25. Suurmeijer AJ Dickson BC Swanson D Zhang L Sung YS Huang HY Fletcher CD Antonescu CR The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements Genes Chromosomes Cancer 2019 58 11 739 746 10.1002/gcc.22767 31112350 PMC6733642 Suurmeijer AJ, Dickson BC, Swanson D, Zhang L, Sung YS, Huang HY, Fletcher CD, Antonescu CR (2019) The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes Chromosomes Cancer 58(11):739–746. 10.1002/gcc.22767 31112350 10.1002/gcc.22767 PMC6733642 26. Suurmeijer AJH Dickson BC Swanson D Zhang L Sung YS Cotzia P Fletcher CDM Antonescu CR A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes Genes Chromosomes Cancer 2018 57 12 611 621 10.1002/gcc.22671 30276917 PMC6746236 Suurmeijer AJH, Dickson BC, Swanson D, Zhang L, Sung YS, Cotzia P, Fletcher CDM, Antonescu CR (2018) A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57(12):611–621. 10.1002/gcc.22671 30276917 10.1002/gcc.22671 PMC6746236 27. Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, et al (2019) Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol 43(4). https://journals.lww.com/ajsp/fulltext/2019/04000/expanding_the_spectrum_of_pediatric.1.aspx 10.1097/PAS.0000000000001203 30585824 ",
  "metadata": {
    "Title of this paper": "A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes",
    "Journal it was published in:": "Virchows Archiv",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488741/"
  }
}